Peripheral nerve graft implants into the substantia nigra of subjects with Parkinson's disease undergoing deep brain stimulation surgery: a safety study

Jorge E. Quintero, Wissam S.Z. Asfahani, Fariba Zaheer, Julie A. Gurwell, Greg A. Gerhardt, John T. Slevin, Craig G. van Horne

1. Introduction
In Parkinson's disease (PD), the substantia nigra undergoes a loss of dopaminergic cells and cellular function. Previous studies have shown that neurotrophic factors including GDNF, BDNF, and NT-3 can promote dopaminergic function. We have begun a Phase I clinical trial to examine the safety and feasibility of implanting an autologous peripheral nerve graft into the substantia nigra of PD patients undergoing deep brain stimulation (DBS) surgery. The Schwann cells in the graft may serve as an alternative source of the growth factors GDNF, NGF, BDNF, and NT-3.

2. Goal
- Examine safety and side effect profile from implanting peripheral nerve tissue into the substantia nigra during DBS surgery.
- Test potential clinical response.

3. Methods

Participant profile:
- Average age = 59.5
- 4 males, 1 female.
- Progressive idiopathic PD >5 yrs
- Medication responsive with motor fluctuations
- Cognitively intact
- Met criteria for DBS surgery

Baseline evaluations:
- Unified Parkinson Disease Rating Scale (UPDRS) on and off medication,
- Quality of life rating (PDQ-8)
- Formal neuropsychological evaluation
- Treat to best patient response

4. DBS surgery provides an avenue for delivering peripheral nerve graft to substantia nigra

Reversed two stage procedure to implant DBS system

Stage I  Implantation of DBS hardware and sural nerve preparation.

Stage II  A) Awake, CRW Frame based surgery B) Microelectrode recordings C) Test stimulations D) Implantation of stimulating electrodes.

Graft harvesting, loading and implantation of graft during Stage II

Harvesting of sural nerve tissue
Implantation of graft
Target: substantia nigra, 1-6mm below base of subthalamic nucleus
Trajectory: 3mm posterolateral to DBS based on visual targeting

5. Off-treatment motor scores improving three months after graft implant

Individual motor scores

Motor Exam On and Off Medication and Stimulation

Motor scores were compared Off stimulation/Off medication and On stimulation and On medication. Additionally, lateralized scores on UPDRS Part III were compared.

6. Imaging results

DBS electrode and graft placement evaluated with 1.5T MRI.

7. Adverse Effects

<table>
<thead>
<tr>
<th>Subject No.</th>
<th>Adverse Event</th>
<th>Status</th>
<th>Relatedness</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Urinary retention</td>
<td>Resolved</td>
<td>procedure</td>
</tr>
<tr>
<td>2</td>
<td>Hypomamia</td>
<td>Resolved</td>
<td>Stimulation</td>
</tr>
<tr>
<td>3</td>
<td>Seizure</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>4</td>
<td>Superficial infection</td>
<td>Resolved</td>
<td>Procedure</td>
</tr>
<tr>
<td>5</td>
<td>Cough, headache</td>
<td>Resolved</td>
<td>Not related to DBS surgery</td>
</tr>
</tbody>
</table>

8. Summary

- Peripheral nerve graft surgery successfully completed in 5 of 5 participants.
- Adverse events comparable to reported effects with DBS surgery.
- Average medication levels decreased after 3 months.
- Motor scores OFF medication and OFF stimulation improved after 3 months.

9. Future Work

- Examine safety and feasibility of bilateral nerve graft implants to the substantia nigra.
- Examine efficacy of nerve graft implant on motor and non-motor symptoms.

10. Acknowledgements
Support provided by University of Kentucky start-up funds (CVH) and CTSA-LILTR000117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Disclosure: CVH receives educational support grant through Medtronic.

Acknowledgement